Skip to content

Advertisement

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes

  • Shivashankar Damodaran1,
  • Nathan Damaschke1,
  • Joseph Gawdzik1,
  • Bing Yang1,
  • Cedric Shi1,
  • Glenn O. Allen1,
  • Wei Huang3,
  • John Denu2, 4, 5 and
  • David Jarrard1, 2, 6, 7Email author
BMC Cancer201717:874

https://doi.org/10.1186/s12885-017-3853-9

Received: 2 August 2017

Accepted: 28 November 2017

Published: 20 December 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
2 Aug 2017 Submitted Original manuscript
8 Sep 2017 Reviewed Reviewer Report - Marjolaine Ngollo
21 Sep 2017 Reviewed Reviewer Report - Gaelle Judes
22 Nov 2017 Author responded Author comments - Shivashankar Damodaran
Resubmission - Version 2
22 Nov 2017 Submitted Manuscript version 2
Publishing
28 Nov 2017 Editorially accepted
20 Dec 2017 Article published 10.1186/s12885-017-3853-9

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, USA
(2)
Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, USA
(3)
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA
(4)
Department of Biomolecular Chemistry, University of Wisconsin, Madison, USA
(5)
Wisconsin Institute for Discovery and the Morgridge Institute for Research, University of Wisconsin, Madison, USA
(6)
Molecular and Environmental Toxicology Program, University of Wisconsin, Madison, USA
(7)
John P. Livesey Chair in Urologic Oncology, Associate Director Translational Research, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Highland, USA

Advertisement